Cargando…

Extent and consequences of inadequate disease control among adults with a history of moderate to severe atopic dermatitis

Since control of atopic dermatitis (AD) remains challenging but has not been adequately characterized, the objective of this study was to characterize disease control among patients with a history of moderate to severe AD. Data were from the 2014 Adelphi US AD Disease Specific Programme, a cross‐sec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wei, Wenhui, Anderson, Peter, Gadkari, Abhijit, Blackburn, Stuart, Moon, Rachel, Piercy, James, Shinde, Shashank, Gomez, Jorge, Ghorayeb, Eric
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813133/ https://www.ncbi.nlm.nih.gov/pubmed/29131384 http://dx.doi.org/10.1111/1346-8138.14116

Ejemplares similares

Discordance Between Physician- and Patient-Reported Disease Severity in Adults with Atopic Dermatitis: A US Cross-Sectional Survey
por: Wei, Wenhui, et al.
Publicado: (2017)

Extent and Impact of Inadequate Disease Control in US Adults with a History of Moderate to Severe Atopic Dermatitis Following Introduction of New Treatments
por: Vilsbøll, Andreas Westh, et al.
Publicado: (2021)

Inadequate Disease Control, Treatment Dissatisfaction, and Quality-of-Life Impairments Among US Patients Receiving Topical Therapy for Atopic Dermatitis
por: Anderson, Peter, et al.
Publicado: (2021)

Profile of dupilumab and its potential in the treatment of inadequately controlled moderate-to-severe atopic dermatitis
por: Awosika, Olabola, et al.
Publicado: (2018)

Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults
por: Kuznik, Andreas, et al.
Publicado: (2017)

The Use of Real-World Data to Evaluate the Association Between Atopic Dermatitis and Cardiovascular Disease: A Retrospective Claims Analysis
por: Wu, Jashin J., et al.
Publicado: (2021)

Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis
por: Simpson, Eric, et al.
Publicado: (2019)

Effects of variations in access to care for children with atopic dermatitis
por: Siegfried, Elaine C., et al.
Publicado: (2020)

Atopic dermatitis
por: Kapur, Sandeep, et al.
Publicado: (2018)

Atopic dermatitis disease registry in Japanese adult patients with moderate to severe atopic dermatitis (ADDRESS‐J): Baseline characteristics, treatment history and disease burden
por: Katoh, Norito, et al.
Publicado: (2019)

Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
por: Bernardo, Diana, et al.
Publicado: (2023)

Impact of Patient and Physician Disconnect on Satisfaction with Treatment for Atopic Dermatitis in Japan
por: Wang, Chaochen, et al.
Publicado: (2022)

Atopic Dermatitis: Natural History, Diagnosis, and Treatment
por: Thomsen, Simon Francis
Publicado: (2014)

Burden of atopic dermatitis in Japanese adults: Analysis of data from the 2013 National Health and Wellness Survey
por: Arima, Kazuhiko, et al.
Publicado: (2018)

Oxidative stress as a treatment target in atopic dermatitis: The role of furfuryl palmitate in mild-to-moderate atopic dermatitis
por: Hebert, Adelaide A.
Publicado: (2020)

Real-world utilization patterns of systemic immunosuppressants among US adult patients with atopic dermatitis
por: Armstrong, April W., et al.
Publicado: (2019)

Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2022)

Association of Moderate–Severe Atopic Dermatitis with Dental Anomalies
por: Tan, Sean Y., et al.
Publicado: (2022)

Natural History and Risk Factors of Atopic Dermatitis in Children
por: Pyun, Bok Yang
Publicado: (2015)

A Comparative Analysis of the Predictors, Extent and Impacts of Self-stigma in Patients with Psoriasis and Atopic Dermatitis
por: SCHLACHTER, Sophie, et al.
Publicado: (2023)

Exploring Immune Development in Infants With Moderate to Severe Atopic Dermatitis
por: Hulshof, Lies, et al.
Publicado: (2018)

Apremilast Use for Moderate-to-Severe Atopic Dermatitis in Pediatric Patients
por: Saporito, Rachael C., et al.
Publicado: (2016)

Correction to: Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2022)

Dupilumab in patients with moderate to severe atopic dermatitis and multiple sclerosis
por: Esposito, Maria, et al.
Publicado: (2022)

Evaluation of standard treatments for managing adult Japanese patients with inadequately controlled moderate‐to‐severe atopic dermatitis: Two‐year data from the ADDRESS‐J disease registry
por: Katoh, Norito, et al.
Publicado: (2022)

Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial
por: Simpson, Eric L., et al.
Publicado: (2019)

TSLP Polymorphisms in Atopic Dermatitis and Atopic March in Koreans
por: Heo, Won Il, et al.
Publicado: (2018)

Atopic dermatitis
por: Werfel, Thomas
Publicado: (2011)

Atopic dermatitis
por: Watson, Wade, et al.
Publicado: (2011)

Atopic dermatitis
por: Galli, Elena, et al.
Publicado: (2020)

Development, Psychometric Validation and Responder Definition of Worst Itch Scale in Children with Severe Atopic Dermatitis
por: Paller, Amy S., et al.
Publicado: (2022)

Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial
por: Paller, Amy S., et al.
Publicado: (2019)

Is Dupilumab as Effective in Intrinsic Atopic Dermatitis as It Is in Extrinsic Atopic Dermatitis?
por: Gelato, Federica, et al.
Publicado: (2023)

Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate‐to‐severe atopic dermatitis
por: Yosipovitch, G., et al.
Publicado: (2019)

Evaluation of a Pseudoceramide Moisturizer in Patients with Mild-to-Moderate Atopic Dermatitis
por: Seghers, Amelie Clementine, et al.
Publicado: (2014)

Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults
por: Xu, Xinghua, et al.
Publicado: (2017)

New Cosmetic Formulation for the Treatment of Mild to Moderate Infantile Atopic Dermatitis
por: de Lucas, Raúl, et al.
Publicado: (2019)

Ocular surface disease is common in moderate‐to‐severe atopic dermatitis patients
por: Achten, Roselie E., et al.
Publicado: (2022)

Population Pharmacokinetics of Tralokinumab in Adult Subjects With Moderate to Severe Atopic Dermatitis
por: Soehoel, Anders, et al.
Publicado: (2022)

Increased Risk of Renal Malignancy in Patients with Moderate to Severe Atopic Dermatitis
por: Oh, Jongwook, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1rst1b48742q6aacfnqg40htt5